rinvoq.com — September 2026 traffic, keywords & AI visibility

rinvoq.com draws an estimated 81,500 visits a month from search engines. Effectively all of it is organic — about 81,300 visits from unpaid results. Paid search contributes only about 210 visits a month. Spread across 2,806 ranking keywords, that averages roughly 29 organic visits per keyword.

On our AI visibility scale rinvoq.com earns 67 of 100 points, a grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on rinvoq.com runs to 171 lines (7,374 characters) across 12 sections, last generated in May 2026. It introduces the site as "RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA". It tells AI engines the business works in Pharmaceuticals, Biotechnology and Immunology. It describes 5 products, including RINVOQ Complete, RINVOQ for PsA and RINVOQ for AD. Services it lists include RINVOQ Connect, Copay Assistance, Provider Education and Safety Monitoring. The audience it names is Chronic illness patients, aged Adults 18-65+ (Global). Technologies it mentions include HTTPS, JavaScript and CSS3. The keywords it claims start with "Rinvoq", "Rinvoq uses", "Rinvoq side effects" and "Rinvoq dosage". It gives the company type as Public.

# RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA

## About
AbbVie develops and markets RINVOQ, a breakthrough once-daily pill revolutionizing treatment for immune-mediated diseases. This JAK inhibitor targets rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, Crohn's disease, polyarticular juvenile idiopathic arthritis, and juvenile psoriatic arthritis. Patients experience significant symptom relief, often where other therapies fail. AbbVie provides full prescribing info, safety data, and boxed warnings for informed use. Their patient assistance programs ensure access regardless of insurance status. Clinical trials demonstrate rapid onset and sustained efficacy across indications. AbbVie leads in immunology with a robust pipeline and real-world evidence collection. Healthcare providers rely on their educational resources and digital tools. Global distribution reaches millions in need. AbbVie's innovation drives better outcomes in chronic care.

**Areas of Work:** Pharmaceuticals, Biotechnology, Immunology

## Things to Remember
- **Website:** https://www.rinvoq.com
- **Address:** North Chicago, Illinois, United States
- **Contact:** 
- **Phone:** 
- **Hours:** 
- **Timezone:** 
- **Currency:** USD
- **Company Type:** Public
- **Employees:** 50,000+
- **Rev

Google lists rinvoq.com for about 2,806 keywords, which together bring an estimated 81,300 organic visits a month.

The latest technical audit of rinvoq.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

AbbVie Inc.'s company profile names https://www.abbvie.com, https://www.jnj.com, https://www.pfizer.com and https://www.drugs.com as competitors. Its own llms.txt adds https://www.humira.com, https://www.xeljanz.com, https://www.oltumiant.com and https://www.skyrizi.com. Outside its market, the domains ranked closest to it in our worldwide ranking are ffsystems.es, vpshispeed.com, simbasleep.com and evc-net.com.

https://www.abbvie.com

https://www.jnj.com

https://www.pfizer.com

https://www.drugs.com

https://www.humira.com

https://www.xeljanz.com

https://www.oltumiant.com

https://www.skyrizi.com